Evidence map›Paper›PMID 36155136›Full record

ArticleThe Lancet. Global health2022

Comparison of maternal and neonatal outcomes of COVID-19 before and after SARS-CoV-2 omicron emergence in maternity facilities in Malawi (MATSurvey): data from a national maternal surveillance platform.

Leonard Mndala, Edward J M Monk, Deborah Phiri, Jennifer Riches, Regina Makuluni, Luis Gadama, Fannie Kachale, Rosemary Bilesi, Malangizo Mbewe, Andrew Likaka and 9 more

Erratum issuedAbstract read
In one paragraph

Article in The Lancet. Global health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Impact of Omicron BA.5 infection on maternal and neonatal outcomes.Frontiers in cellular and infection microbiology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Maternal and Perinatal Outcomes of SARS-CoV-2 and Variants in Pregnancy.Maternal-fetal medicine (Wolters Kluwer Health, Inc.) · 2023
    Article
  14. Observational
  15. Article
  16. Review
  17. Observational
  18. COVID-19 in pregnancy: evidence from LMICs.The Lancet. Global health · 2022
    Article
  19. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Leonard MndalaMalawi-Liverpool-Wellcome Clinical Research Programme, Blantyre, Malawi.
Edward J M MonkMalawi-Liverpool-Wellcome Clinical Research Programme, Blantyre, Malawi. Electronic address: emonk@mlw.mw.
Deborah PhiriMalawi-Liverpool-Wellcome Clinical Research Programme, Blantyre, Malawi.
Jennifer RichesMalawi-Liverpool-Wellcome Clinical Research Programme, Blantyre, Malawi.
Regina MakuluniMalawi-Liverpool-Wellcome Clinical Research Programme, Blantyre, Malawi.
Luis GadamaKamuzu University of Health Sciences, Blantyre, Malawi.
Fannie KachaleMinistry of Health, Lilongwe, Malawi.
Rosemary BilesiMinistry of Health, Lilongwe, Malawi.
Malangizo MbeweMinistry of Health, Lilongwe, Malawi.
Andrew LikakaMalawi Blood Transfusion Services, Blantyre, Malawi; Universidade Federal de Pernambuco, Recife, Brazil.
Chikondi ChapumaMalawi-Liverpool-Wellcome Clinical Research Programme, Blantyre, Malawi.
Moses KumwendaMalawi-Liverpool-Wellcome Clinical Research Programme, Blantyre, Malawi; Kamuzu University of Health Sciences, Blantyre, Malawi.
Bertha MasekoMalawi-Liverpool-Wellcome Clinical Research Programme, Blantyre, Malawi.
Chifundo NdamalaMalawi-Liverpool-Wellcome Clinical Research Programme, Blantyre, Malawi.
Annie KuyereMalawi-Liverpool-Wellcome Clinical Research Programme, Blantyre, Malawi.
Laura MunthaliMalawi-Liverpool-Wellcome Clinical Research Programme, Blantyre, Malawi.
Marc Y R HenrionMalawi-Liverpool-Wellcome Clinical Research Programme, Blantyre, Malawi; Liverpool School of Tropical Medicine, Liverpool, UK.
Clemens MasesaMalawi-Liverpool-Wellcome Clinical Research Programme, Blantyre, Malawi; Liverpool School of Tropical Medicine, Liverpool, UK.
David LissauerMalawi-Liverpool-Wellcome Clinical Research Programme, Blantyre, Malawi; University of Liverpool, Liverpool, UK.

Funding

Malawi HIV Implementation Research Scientist Training Program (MHIRST)D43TW010060 · FIC · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MINA CHRISTINE HOSSEINIPOUR, Victor Mwapasa · 2015 to 2026
$3.8M
FIC NIH HHS D43 TW010060Wellcome TrustWellcome Trust 206545/Z/17/Z
6 · The paper itself

Abstract

backgroundOutcomes of omicron-associated COVID-19 in pregnancy have not been reported from low-resource settings, and data from sub-Saharan Africa before the emergence of omicron are scarce. Using a national maternal surveillance platform (MATSurvey), we aimed to compare maternal and neonatal outcomes of COVID-19 in Malawi during the omicron wave to the preceding waves of beta and delta.

methodsAll pregnant and recently pregnant patients, up to 42 days following delivery, admitted to 33 health-care facilities throughout Malawi with symptomatic, test-proven COVID-19 during the second (beta [B.1.351]: January to April, 2021), third (delta [B.1.617.2]: June to October, 2021), and fourth (omicron [B.1.1.529]: December 2021 to March, 2022) waves were included, with no age restrictions. Demographic and clinical features, maternal outcomes of interest (severe maternal outcome [a composite of maternal near-miss events and maternal deaths] and maternal death), and neonatal outcomes of interest (stillbirth and death during maternal stay in the health-care facility of enrolment) were compared between the fourth wave and the second and third waves using Fisher's exact test. Adjusted odds ratios (ORs) for maternal outcomes were estimated using mixed-effects logistic regression.

findingsBetween Jan 1, 2021, and March 31, 2022, 437 patients admitted to 28 health-care facilities conducting MATSurvey had symptoms of COVID-19. SARS-CoV-2 infection was confirmed in 261 patients; of whom 76 (29%) had a severe maternal outcome and 45 (17%) died. These two outcomes were less common during the fourth wave (omicron dominance) than the second wave (adjusted OR of severe maternal outcome: 3·96 [95% CI 1·22-12·83], p=0·022; adjusted OR of maternal death: 5·65 [1·54-20·69], p=0·0090) and the third wave (adjusted OR: 3·18 [1·03-9·80], p=0·044; adjusted OR: 3·52 [0·98-12·60], p=0·053). Shortness of breath was the only symptom associated with poor maternal outcomes of interest (p<0·0001), and was less frequently reported in the fourth wave (23%) than in the second wave (51%; p=0·0007) or third wave (50%; p=0·0004). The demographic characteristics and medical histories of patients were similar across the three waves. During the second and third waves, 12 (13%) of 92 singleton neonates were stillborn or died during maternal stay in the health-care facility of enrolment, compared with 0 of the 25 born in the fourth wave (p=0·067 vs preceding waves combined).

interpretationMaternal and neonatal outcomes from COVID-19 were less severe during the fourth wave of the SARS-CoV-2 pandemic in Malawi, during omicron dominance, than during the preceding beta and delta waves.

fundingBill & Melinda Gates Foundation, Wellcome Trust, and the National Institute for Health and Care Research. TRANSLATION: For the Chichewa translation of the abstract see Supplementary Materials section.

Indexed as

COVID-19Maternal DeathPregnancy Complications, InfectiousFemaleHumansInfant, NewbornMalawiPregnancySARS-CoV-2Stillbirth

Identifiers

PMID36155136
PMCPMC9553200

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.